Added to YB: 2026-10-08
Pitch date: 2026-10-06
NAUT [bullish]
Nautilus Biotechnology, Inc.
+29.34%
current return
Author Info
No bio for this author
Company Info
Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome in the United States.
Market Cap
$238.0M
Pitch Price
$1.67
Price Target
N/A
Dividend
N/A
EV/EBITDA
-3.54
P/E
-4.19
EV/Sales
956.59
Sector
Life Sciences Tools and Services
Category
growth
All Roads Lead to Nautilus Biotechnology
NAUT (update): Nautilus Biotechnology is a pre-commercial bet that proteoform-resolution data becomes the functional layer AI needs for predictive biology; its platform keeps proteins intact to identify coexisting modifications, unlike conventional bottom-up proteomics. Assay development is accelerating, with management targeting roughly 20 vertical assays by mid-2028. At a ~$240M market cap versus a stated multibillion-dollar value thesis, upside is substantial, but financing, execution and bankruptcy risk could break the case.
Read full article (10 min)